Research advances in animal models of nonalcoholic fatty liver disease

Huang HaiYan; Xin YongNing; Jiang Man; Jin WenWen; Jiang XiangJun; Xuan ShiYing

doi:10.3969/j.issn.1001-5256.2014.09.028

Issue 9

Sep. 2014

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2014 > 30(9): 948-953

PDF( 1355 KB)

Research advances in animal models of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2014.09.028

Taishan Medical University

Research funding:

Received Date: 2014-02-13
Published Date: 2014-09-20

Abstract

Abstract

In recent years, the incidence of nonalcoholic fatty liver disease ( NAFLD) has increased gradually along with the rising prevalence of obesity, type 2 diabetes, and hyperlipidemia, and NAFLD has become one of the most common chronic liver diseases in the world and the second major liver disease after chronic viral hepatitis in China. However, its pathogenesis has not yet been clarified. Animal models are playing an important role in researches on NAFLD due to the facts that the development and progression of NAFLD require a long period of time, and ethical limitations exist in conducting drug trials in patients or collecting liver tissues from patients. The animal models with histopathology similar to that of NAFLD patients are reviewed, and their modeling principle, as well as the advantages and disadvantages, are compared. Animal models provide a powerful tool for further studies of NAFLD pathogenesis and drug screening for prevention and treatment of NAFLD.
- fatty liver,
- disease models, animal,
- mice,
- review

FullText(HTML)

References(48)

References

[1] PAPPACHAN JM, ANTONIO FA, EDAVALATH M, et al.Non-alcoholic fatty liver disease:a diabetologist's perspective[J].Endocrine, 2014, 45 (3) :344-353.

[2] GOH VJ, SILVER DL.The lipid droplet as a potential therapeutic target in NAFLD[J].Semin Liver Dis, 2013, 33 (4) :312-320.

[3] MIKOLASEVIC I, RACKI S, ZAPUTOVIC L, et al.Nonalcoholic fatty liver disease (NAFLD) :a new risk factor for adverse cardiovascular events in dialysis patients[J].Med Hypotheses, 2014, 82 (2) :205-208.

[4]HEBBARD L, GEORGE J.Animal models of nonalcoholic fatty liver disease[J].Nat Rev Gastroenterol Hepatol, 2011, 8 (1) :35-44.

[5]REDDY SK, ZHAN M, ALEXANDER HR, et al.Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders[J].World J Gastroenterol, 2013, 19 (45) :8301-8311.

[6]IMAJO K, YONEDA M, KESSOKU T, et al.Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].Int J Mol Sci, 2013, 14 (11) :21833-21857.

[7]KANURI G, BERGHEIM I.In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD) [J].Int J Mol Sci, 2013, 14 (6) :11963-11980.

[8]GUEBRE-XABIER M, YANG S, LIN HZ, et al.Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers:potential mechanism for sensitization to liver damage[J].Hepatology, 2000, 31 (3) :633-640.

[9]LECLERCQ IA, FARRELL GC, FIELD J, et al.CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis[J].J Clin Invest, 2000, 105 (8) :1067-1075.

[10] KAPLAN LM.Leptin, obesity, and liver disease[J].Gastroenterology, 1998, 115 (4) :997-1001.

[11]SAHAI A, MALLADI P, PAN X, et al.Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis:role of short-form leptin receptors and osteopontin[J].Am J Physiol Gastrointest Liver Physiol, 2004, 287 (5) :g1035-g1043.

[12]ZHANG DD, JIANG M, XIN YN, et al.Construction of lentivirus vectors containing PNPLA3 gene and overexpression of PNPLA3 in Huh-7 cells[J].Chin J Hepatol, 2013, 21 (3) :236-238. (in Chinese) 张丁丁, 姜曼, 辛永宁, 等.PNPLA3基因慢病毒载体及其过表达Huh-7细胞系的构建[J].中华肝脏病杂志, 2013, 21 (3) :236-238.

[13]ROTMAN Y, KOH C, ZMUDA JM, et al.The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease[J].Hepatology, 2010, 52 (3) :894-903.

[14] LI JZ, HUANG Y, KARAMAN R, et al.Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis[J].J Clin Invest, 2012, 122 (11) :4130-4144.

[15]HAO Q, HANSEN JB, PETERSEN RK, et al.ADD1/SREBP1c activates the PGC1-alpha promoter in brown adipocytes[J].Biochim Biophys Acta, 2010, 1801 (4) :421-429.

[16]ESPENSHADE PJ.SREBPs:sterol-regulated transcription factors[J].J Cell Sci, 2006, 119 (Pt 6) :973-976.

[17] NAKAYAMA H, OTABE S, UENO T, et al.Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis[J].Metabolism, 2007, 56 (4) :470-475.

[18]SHIMOMURA I, HAMMER RE, RICHARDSON JA, et al.Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue:model for congenital generalized lipodystrophy[J].Genes Dev, 1998, 12 (20) :3182-3194.

[19]SCHATTENBERG JM, GALLE PR.Animal models of non-alcoholic steatohepatitis:of mice and man[J].Dig Dis, 2010, 28 (1) :247-254.

[20]MASAKI T, CHIBA S, TATSUKAWA H, et al.Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KKAy obese mice[J].Hepatology, 2004, 40 (1) :177-184.

[21]MYERS MP, STOLAROV JP, ENG C, et al.P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase[J].Proc Natl Acad Sci U S A, 1997, 94 (17) :9052-9057.

[22] HE L, HOU X, KANEL G, et al.The critical role of AKT2 in hepatic steatosis induced by PTEN loss[J].Am J Pathol, 2010, 176 (5) :2302-2308.

[23] SVEGLIATI-BARONI G, CANDELARESI C, SACCOMANNO S, et al.A model of insulin resistance and nonalcoholic steatohepatitis in rats:role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury[J].Am J Pathol, 2006, 169 (3) :846-860.

[24]KERSTEN S, SEYDOUX J, PETERS JM, et al.Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting[J].J Clin Invest, 1999, 103 (11) :1489-1498.

[25]REDDY JK.Nonalcoholic steatosis and steatohepatitis.Ⅲ.Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis[J].Am J Physiol Gastrointest Liver Physiol, 2001, 281 (6) :g1333-g1339.

[26] LONDON RM, GEORGE J.Pathogenesis of NASH:animal models[J].Clin Liver Dis, 2007, 11 (1) :55-74.

[27]LU SC, ALVAREZ L, HUANG ZZ, et al.Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation[J].Proc Natl Acad Sci U S A, 2001, 98 (10) :5560-5565.

[28] COOK WS, JAIN S, JIA Y, et al.Peroxisome proliferator-activated receptor alpha-responsive genes induced in the newborn but not prenatal liver of peroxisomal fatty acyl-CoA oxidase null mice[J].Exp Cell Res, 2001, 268 (1) :70-76.

[29]COBURN CT, KNAPP FJ, FEBBRAIO M, et al.Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice[J].J Biol Chem, 2000, 275 (42) :32523-32529.

[30]MA KL, RUAN XZ, POWIS SH, et al.Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice[J].Hepatology, 2008, 48 (3) :770-781.

[31]TAKAHASHI Y, SOEJIMA Y, FUKUSATO T.Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].World J Gastroenterol, 2012, 18 (19) :2300-2308.

[32]DENG QG, SHE H, CHENG JH, et al.Steatohepatitis induced by intragastric overfeeding in mice[J].Hepatology, 2005, 42 (4) :905-914.

[33]ITO M, SUZUKI J, TSUJIOKA S, et al.Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to highfat diet[J].Hepatol Res, 2007, 37 (1) :50-57.

[34] de ALWIS NM, DAY CP.Non-alcoholic fatty liver disease:the mist gradually clears[J].J Hepatol, 2008, 48 (Suppl 1) :s104-s112.

[35] ANSTEE QM, GOLDIN RD.Mouse models in non-alcoholic fatty liver disease and steatohepatitis research[J].Int J Exp Pathol, 2006, 87 (1) :1-16.

[36] DELA PA, LECLERCQ I, FIELD J, et al.NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis[J].Gastroenterology, 2005, 129 (5) :1663-1674.

[37]LECLERCQ IA, FARRELL GC, FIELD J, et al.CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis[J].J Clin Invest, 2000, 105 (8) :1067-1075.

[38]IP E, FARRELL G, HALL P, et al.Administration of the potent PPARalpha agonist, Wy-14, 643, reverses nutritional fibrosis and steatohepatitis in mice[J].Hepatology, 2004, 39 (5) :1286-1296.

[39] LARTER CZ, YEH MM.Animal models of NASH:getting both pathology and metabolic context right[J].J Gastroenterol Hepatol, 2008, 23 (11) :1635-1648.

[40] KIRSCH R, CLARKSON V, SHEPHARD EG, et al.Rodent nutritional model of non-alcoholic steatohepatitis:species, strain and sex difference studies[J].J Gastroenterol Hepatol, 2003, 18 (11) :1272-1282.

[41] ACKERMAN Z, ORON-HERMAN M, GROZOVSKI M, et al.Fructose-induced fatty liver disease:hepatic effects of blood pressure and plasma triglyceride reduction[J].Hypertension, 2005, 45 (5) :1012-1018.

[42] ARMUTCU F, COSKUN O, GUREL A, et al.Thymosin alpha 1attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats[J].Clin Biochem, 2005, 38 (6) :540-547.

[43]KOHLI R, KIRBY M, XANTHAKOS SA, et al.High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis[J].Hepatology, 2010, 52 (3) :934-944.

[44]XING LX, HE YW.Experiment study on nonalcoholic fatty liver model induced by injection of oxytetracycline intraperitoneally in rats[J].J Clin Hepatol, 2007, 23 (1) :29-31. (in Chinese) 邢凌翔, 贺永文.氧四环素腹腔注射制备大鼠非酒精性脂肪肝模型的实验研究[J].临床肝胆病杂志, 2007, 23 (1) :29-31.

[45]WANG L, LYU JH, RAO WY, et al.Effect of baogan tablets on hepatic fibrosis induced by carbon tetrachloride complex factors in rats[J].Chin J Exp Med Formul, 2013, 19 (7) :234-236. (in Chinese) 王丽, 吕纪华, 饶伟源, 等.保肝片对大鼠肝纤维化模型的影响[J].中国实验方剂学杂志, 2013, 19 (7) :234-236.

[46] SINHA-HIKIM I, SINHA-HIKIM AP, SHEN R, et al.A novel cystine based antioxidant attenuates oxidative stress and hepatic steatosis in diet-induced obese mice[J].Exp Mol Pathol, 2011, 91 (1) :419-428.

[47] KASHIREDDY PV, RAO MS.Lack of peroxisome proliferator-activated receptor alpha in mice enhances methionine and choline deficient diet-induced steatohepatitis[J].Hepatol Res, 2004, 30 (2) :104-110.

[48]JU DH, ZHAO HY, LIU MJ.Advances in animal models of nonalcoholic fatty liver disease that combine disease and syndromes[J].World Chin J Dig, 2010, 18 (14) :1452-1455. (in Chinese) 鞠大宏, 赵宏艳, 刘梅洁.非酒精性脂肪性肝病病证结合动物模型的研究进展[J].世界华人消化杂志, 2010, 18 (14) :1452-1455.引证本文:HUANG HY, XIN YN, JIANG M, et al.Research advances in animal models of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2014, 30 (9) :948-953. (in Chinese) 黄海燕, 辛永宁, 姜曼, 等.非酒精性脂肪性肝病动物实验模型研究进展[J].临床肝胆病杂志, 2014, 30 (9) :948-953.

Relative Articles

[1]	Lou Xin, Gao YuFeng, Ye Jun, Wang YinQiu, Guan ZiShu, Zou GuiZhou. Clinical effect of pegylated interferon α-2a in treatment of previously untreated HBeAg-positive chronic hepatitis B patients and related predictive factors[J]. Journal of Clinical Hepatology, 2018, 34(5): 995-1000. doi: 10.3969/j.issn.1001-5256.2018.05.014
[2]	Yang PuJuan, Huang Yi, Liu HuaBao. Research advances in the association between interleukin-17 and liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(9): 1810-1814. doi: 10.3969/j.issn.1001-5256.2017.09.041
[3]	Li KeXin, Zang MengYa, Wang DongMei, He Huan, Wang YuTing, Qu ChunFeng. Effect of interleukin-17A on stemness of hepatoma cell lines[J]. Journal of Clinical Hepatology, 2017, 33(6): 1131-1136. doi: 10.3969/j.issn.1001-5256.2017.06.023
[4]	Gao Na, Wu RuiHong, Wang XiaoMei, Niu JunQi. Value of HBsAg quantification in predicting the prognosis of patients with chronic severe hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(4): 695-699. doi: 10.3969/j.issn.1001-5256.2016.04.017
[5]	Wang Wei, Rong Jun, Li LiHua, Niu HongYao, Gao HengBo, Zheng HuanWei. Association between dynamic changes in HBsAg and progression of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(6): 1204-1206. doi: 10.3969/j.issn.1001-5256.2016.06.044
[6]	Zhang HaiYue, Zhou Pei, Gong ZuoJiong. Predictive value of HBs Ag quantification in pegylated interferon therapy for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(5): 977-980. doi: 10.3969/j.issn.1001-5256.2016.05.041
[7]	Li XiaoTian, Yin Yan, Guo YongZe, Zhou LiYun, You ZiXuan. Mechanism of action of 1,25(OH)_2D_3 in influencing the expression of interleukin-17 and macrophage inflammatory protein-3α and inhibiting the formation of liver fibrosis in rats[J]. Journal of Clinical Hepatology, 2016, 32(12): 2331-2336. doi: 10.3969/j.issn.1001-5256.2016.12.020
[8]	Hao TingTing, Ma XiaoPeng, Wen YanLi, Dai GuangRong, Feng YiChao, Zhang Li. Changes in serum levels of M30,M65,and IL-17 and their clinical significance in patients with acute pancreatitis[J]. Journal of Clinical Hepatology, 2016, 32(2): 329-332. doi: 10.3969/j.issn.1001-5256.2016.02.027
[9]	Li HuoYan, Yang ZhaoHui, Ma LiLi, Ma Long. Clinical efficacy of telbivudine and interferon in treatment of HBe Ag-positive chronic hepatitis B: a comparative study[J]. Journal of Clinical Hepatology, 2015, 31(4): 526-529. doi: 10.3969/j.issn.1001-5256.2015.04.012
[10]	Xian YongChao, Cheng ShuQuan, Ni Hui, Huang ChengJun. Analysis of hepatic CD4~+,CD8~+,CD20~+,and CD57~+ T lymphocytes in chronic hepatitis B patients with different HBe Ag status[J]. Journal of Clinical Hepatology, 2015, 31(4): 546-550. doi: 10.3969/j.issn.1001-5256.2015.04.017
[11]	Liu ZhiHua, He HaiTang, Hu Jing, Fu QunXiang, Luo KangXian. Efficacy of pegylated interferon α-2a in HBe Ag-negative chronic hepatitis B patients and its influencing factors[J]. Journal of Clinical Hepatology, 2015, 31(5): 697-701. doi: 10.3969/j.issn.1001-5256.2015.05.016
[12]	Li CaiDong, Yang YongWei, Li HuiJun, Tian PengFei, Wu Bin. Changes in peripheral plasma concentrations of macrophage migration inhibitory factor,interleukin-17,and interleukin-10 and their correlations with HBV DNA load in chronic HBV carriers[J]. Journal of Clinical Hepatology, 2015, 31(5): 702-705. doi: 10.3969/j.issn.1001-5256.2015.05.017
[13]	Wu Qin, Meng FanPing, Ma XueMei, Jin Bo, Shen LiJun, Wu LiBing, Chu JinDong, Lai WenHui, Han JingJing, Li HanWei. Analysis of association between different HCV genotypes and serum interleukin-17, interleukin-6, and vitamin D in patients with HCV-related cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1849-1852. doi: 10.3969/j.issn.1001-5256.2015.11.019
[14]	Guan HaiTao, Zhao JinLi, Tang Rui, Sun LinLin. IL-17 promotes expression of fibrosis-related factors in hepatic stellate cells[J]. Journal of Clinical Hepatology, 2013, 29(5): 370-374.
[15]	Wu YinYa, Tan ShanZhong, Zhao Lei, Sun WeiWei, Shen JianJun, Liang ZhongFeng. The changes and value of the proportion of CD4+CD25+ regulatory T cells in HBeAg (+) and HBeAg (-) ASC in peripheral blood[J]. Journal of Clinical Hepatology, 2012, 28(3): 209-211.
[16]	Yang ZhiYong, Yang Qian, Xiao GuiBao, Zhao HeHong, Feng Ping. Clinical observation of the relation between the HBeAg and HBV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2012, 28(4): 270-272.
[17]	Qin JianJie, Lu: Ling. The role and molecular mechanism of interleukin-17 in organ transplant rejection[J]. Journal of Clinical Hepatology, 2012, 28(11): 812-814.
[18]	Wu YuZhuo. Correlation analysis of quantitative HBsAg and liver histological features of HBeAg-negative chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(12): 923-925.
[19]	Jin Rui, Zhang ShiBin, Bian XinQu, Lu ChengZhen, Liu ZhongSheng, Guo XinHui. Clinical study of IFNα-2b alone or in combination with lamivudine for HBeAg positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(6): 617-619.
[20]	Yao QinJiang, Ma WeiGuo. Therapeutic efficacy of telbivudine in hepatitis B e antigen positive chronic hepatitis B patients with high baseline alanine aminotransferase levels[J]. Journal of Clinical Hepatology, 2011, 27(6): 614-616.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	粟雨萌，张鸣杰，谈振华，谢平. 胰十二指肠切除术后发生胃排空延迟的危险因素分析. 肝胆胰外科杂志. 2024(10): 608-611+616 .
2.	张苗苗，白纪刚，张东，雷建军，耿智敏，冯爱芳，董芳芳，史爱华，吕毅，严小鹏. 用于胰十二指肠切除术中Braun吻合磁环的设计及临床应用. 中国医疗设备. 2022(06): 8-11 .
3.	李利平，游意莹，沈宁，曹宏，王艳玲. 改良内陷式胰肠吻合在胰十二指肠切除术中的应用. 中华肝脏外科手术学电子杂志. 2022(05): 458-462 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3159) PDF downloads(586)

Research advances in animal models of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2014.09.028